Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | DDX3X | O00571 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749248 | 0.93 | USP2 (0.48) | USP2ALDH1A1TSHRCYP3A4CYP2C19 | |
| SCHEMBL25787726 | 0.85 | USP2 (0.43) | USP2ALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL20551929 | 0.83 | USP2 (0.48) | USP2ALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL25787729 | 0.83 | USP2 (0.42) | USP2ALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL25787764 | 0.80 | LMNA (0.42) | USP2TSHRSMN1; SMN2MAPTLMNA | |
| SCHEMBL21749260 | 0.79 | ABCG2 (0.42) | USP2TSHRSMN1; SMN2MAPTLMNA | |
| SCHEMBL25787720 | 0.79 | KMT2A (0.42) | USP2ALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL25787836 | 0.78 | ABCG2 (0.41) | USP2SMN1; SMN2MAPTLMNAABCG2 | |
| SCHEMBL20552459 | 0.77 | ABCG2 (0.47) | ALDH1A1TSHRSMN1; SMN2MAPTLMNA | |
| SCHEMBL25787068 | 0.77 | SMN1; SMN2 (0.40) | USP2ALDH1A1TSHRCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | USP2 2622/4885ALDH1A1 3323/4885TSHR 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.